Shionogi's S-033188 meets in Phase III for influenza

Shionogi & Co. Ltd. (Tokyo:4507) reported top-line data from the Phase III CAPSTONE-1 trial in 1,436 patients with influenza A or B infection showing that oral S-033188 met the primary endpoint of reducing time to alleviation of symptoms vs. placebo (p<0.0001). Time to alleviation of symptoms was defined as the time when all of 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) have been assessed by the patient as being alleviated at each prespecified time point.

Patients in the double-blind, international trial received placebo, the neuraminidase inhibitor Tamiflu oseltamivir for 5 days, or a single dose of 40 or 80 mg S-033188 depending on body weight...